Pharmacogenetic covariation of defective N-oxidation of sparteine and 4-hydroxylation of debrisoquine.

Deletion of the entire cytochrome P450 CYP2D6 gene as a cause of impaired drug metabolism in poor metabolizers of the debrisoquine/sparteine polymorphism. Am J Hum Genet (1991) 1.60

Evidence for an enzymatic defect in the 4-hydroxylation of debrisoquine by human liver. Br J Clin Pharmacol (1981) 1.47

Antipyrine metabolism in relation to polymorphic oxidations of sparteine and debrisoquine. Br J Clin Pharmacol (1983) 1.21

Genetically determined oxidation capacity and the disposition of debrisoquine. Br J Clin Pharmacol (1983) 1.19

Evaluation of probe drugs and pharmacokinetic metrics for CYP2D6 phenotyping. Eur J Clin Pharmacol (2007) 1.14

Inhibitory effects of neuroleptics on debrisoquine oxidation in man. Br J Clin Pharmacol (1986) 1.13

The debrisoquine hydroxylation test predicts steady-state plasma levels of desipramine. Br J Clin Pharmacol (1983) 1.11

Pharmacogenomics: the genetics of variable drug responses. Circulation (2011) 1.10

Clinically relevant genetic variations in drug metabolizing enzymes. Curr Drug Metab (2011) 0.99

Evidence for polymorphic oxidation of sparteine in Japanese subjects. Br J Clin Pharmacol (1987) 0.99

The contribution of genetically determined oxidation status to inter-individual variation in phenacetin disposition. Br J Clin Pharmacol (1983) 0.95

6 beta-hydroxycortisol excretion in relation to polymorphic N-oxidation of sparteine. Br J Clin Pharmacol (1982) 0.94

Defective hydroxylation of bufuralol associated with side-effects of the drug in poor metabolisers. Br J Clin Pharmacol (1982) 0.91

Assay and characterisation of debrisoquine 4-hydroxylase activity of microsomal fractions of human liver. Br J Clin Pharmacol (1982) 0.91

Pharmacogenetics: implementing personalized medicine. Clin Cases Miner Bone Metab (2009) 0.83

Urinary bile acid and bile alcohol excretion does not reflect the genetic polymorphism of debrisoquine hydroxylation. Br J Clin Pharmacol (1984) 0.75

Development of analytical technology in pharmacogenetic research. Naunyn Schmiedebergs Arch Pharmacol (2003) 0.75

Functional polymorphisms of the human multidrug-resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo. Proc Natl Acad Sci U S A (2000) 5.89

Defective N-oxidation of sparteine in man: a new pharmacogenetic defect. Eur J Clin Pharmacol (1979) 3.78

Extensive genetic polymorphism in the human CYP2B6 gene with impact on expression and function in human liver. Pharmacogenetics (2001) 3.05

Disassociation between debrisoquine hydroxylation phenotype and genotype among Chinese. Lancet (1989) 2.96

Nuclear receptor response elements mediate induction of intestinal MDR1 by rifampin. J Biol Chem (2001) 2.62

Frequency of single nucleotide polymorphisms in the P-glycoprotein drug transporter MDR1 gene in white subjects. Clin Pharmacol Ther (2001) 2.62

The role of intestinal P-glycoprotein in the interaction of digoxin and rifampin. J Clin Invest (1999) 2.57

Predictive value of known and novel alleles of CYP2B6 for efavirenz plasma concentrations in HIV-infected individuals. Clin Pharmacol Ther (2007) 2.48

Risks of solid cancers in patients with rheumatoid arthritis and after treatment with tumour necrosis factor antagonists. Ann Rheum Dis (2005) 2.46

Haematopoietic malignancies in rheumatoid arthritis: lymphoma risk and characteristics after exposure to tumour necrosis factor antagonists. Ann Rheum Dis (2005) 2.43

Polymorphic oxidation of sparteine and debrisoquine: related pharmacogenetic entities. Clin Pharmacol Ther (1982) 2.26

Defective oxidation of drugs: pharmacokinetic and therapeutic implications. Clin Pharmacokinet (1982) 2.19

Genetic analysis of the Chinese cytochrome P4502D locus: characterization of variant CYP2D6 genes present in subjects with diminished capacity for debrisoquine hydroxylation. Mol Pharmacol (1994) 2.09

Comprehensive analysis of the genetic factors determining expression and function of hepatic CYP2D6. Pharmacogenetics (2001) 2.08

Inherited amplification of an active gene in the cytochrome P450 CYP2D locus as a cause of ultrarapid metabolism of debrisoquine. Proc Natl Acad Sci U S A (1993) 2.08

The teaching and organisation of clinical pharmacology in European medical schools (W.H.O. Working Group on Clinical Pharmacology). Eur J Clin Pharmacol (1990) 2.07

Frequency of C3435T polymorphism of MDR1 gene in African people. Lancet (2001) 2.02

Activity levels of tamoxifen metabolites at the estrogen receptor and the impact of genetic polymorphisms of phase I and II enzymes on their concentration levels in plasma. Clin Pharmacol Ther (2011) 1.98

Identification of the primary gene defect at the cytochrome P450 CYP2D locus. Nature (1990) 1.96

Nomenclature for human CYP2D6 alleles. Pharmacogenetics (1996) 1.91

Molecular basis for rational megaprescribing in ultrarapid hydroxylators of debrisoquine. Lancet (1993) 1.87

Mutation in the SPINK1 trypsin inhibitor gene, alcohol use, and chronic pancreatitis. JAMA (2001) 1.81

10-Hydroxylation of nortriptyline in white persons with 0, 1, 2, 3, and 13 functional CYP2D6 genes. Clin Pharmacol Ther (1998) 1.72

Physiological disposition of verapamil in man. Cardiovasc Res (1976) 1.71

Anti-tumour necrosis factor therapy in rheumatoid arthritis and risk of malignant lymphomas: relative risks and time trends in the Swedish Biologics Register. Ann Rheum Dis (2008) 1.69

Safe treatment of thiopurine S-methyltransferase deficient Crohn's disease patients with azathioprine. Gut (2003) 1.66

Assessment of the predictive power of genotypes for the in-vivo catalytic function of CYP2D6 in a German population. Pharmacogenetics (1998) 1.64

Clinical pharmacokinetics and pharmacological effects of carbamazepine and carbamazepine-10,11-epoxide. An update. Clin Pharmacokinet (1986) 1.63

Debrisoquine hydroxylation polymorphism and personality. Lancet (1989) 1.62

Plasma kinetics of carbamazepine and its epoxide metabolite in man after single and multiple doses. Eur J Clin Pharmacol (1975) 1.60

Deletion of the entire cytochrome P450 CYP2D6 gene as a cause of impaired drug metabolism in poor metabolizers of the debrisoquine/sparteine polymorphism. Am J Hum Genet (1991) 1.60

Natural protein variants of pregnane X receptor with altered transactivation activity toward CYP3A4. Drug Metab Dispos (2001) 1.58

Debrisoquine/sparteine hydroxylation genotype and phenotype: analysis of common mutations and alleles of CYP2D6 in a European population. DNA Cell Biol (1991) 1.57

Antiepileptic drugs increase plasma levels of 4beta-hydroxycholesterol in humans: evidence for involvement of cytochrome p450 3A4. J Biol Chem (2001) 1.57

Polymorphic drug oxidation in humans. Fed Proc (1984) 1.53

Same incidence of adverse drug events after codeine administration irrespective of the genetically determined differences in morphine formation. Pain (1998) 1.52

Monoamine metabolites in CSF and suicidal behavior. Arch Gen Psychiatry (1981) 1.52

An enantiomer-enantiomer interaction of (S)- and (R)-propafenone modifies the effect of racemic drug therapy. Circulation (1994) 1.52

Frequent distribution of ultrarapid metabolizers of debrisoquine in an ethiopian population carrying duplicated and multiduplicated functional CYP2D6 alleles. J Pharmacol Exp Ther (1996) 1.51

Slow omeprazole metabolizers are also poor S-mephenytoin hydroxylators. Ther Drug Monit (1990) 1.50

The C3435T mutation in the human MDR1 gene is associated with altered efflux of the P-glycoprotein substrate rhodamine 123 from CD56+ natural killer cells. Pharmacogenetics (2001) 1.50

Characterization of the major metabolites of verapamil as substrates and inhibitors of P-glycoprotein. J Pharmacol Exp Ther (2000) 1.48

Pharmacokinetics of pindolol in man. Eur J Clin Pharmacol (1974) 1.46

Why are diazepam metabolism and polymorphic S-mephenytoin hydroxylation associated with each other in white and Korean populations but not in Chinese populations? Clin Pharmacol Ther (1993) 1.46

Pharmacokinetics of oral and intravenous rifampicin during chronic administration. Klin Wochenschr (1985) 1.46

Low frequency of slow debrisoquine hydroxylation in a native Chinese population. Lancet (1987) 1.42

Differential induction of prehepatic and hepatic metabolism of verapamil by rifampin. Hepatology (1996) 1.42

Clinical pharmacokinetics of carbamazepine. Clin Pharmacokinet (1978) 1.42

Is there a genetic factor in flecainide toxicity? BMJ (1988) 1.41

S-mephenytoin hydroxylation phenotypes in a Swedish population determined after coadministration with debrisoquin. Clin Pharmacol Ther (1989) 1.41

E- and Z-10-hydroxylation of nortriptyline: relationship to polymorphic debrisoquine hydroxylation. Clin Pharmacol Ther (1981) 1.41

Presentation of results from bioequivalence studies. Int J Clin Pharmacol Ther Toxicol (1992) 1.40

Stereoselective first-pass metabolism of highly cleared drugs: studies of the bioavailability of L- and D-verapamil examined with a stable isotope technique. Br J Clin Pharmacol (1984) 1.39

The metabolism of DL-[14C]verapamil in man. Drug Metab Dispos (1979) 1.39

The role of human cytochrome P450 enzymes in the metabolism of anticancer agents: implications for drug interactions. Br J Clin Pharmacol (1995) 1.39

Polymorphic debrisoquin hydroxylation in 757 Swedish subjects. Clin Pharmacol Ther (1988) 1.37

The effect of dextro-, levo-, and racemic verapamil on atrioventricular conduction in humans. Am Heart J (1985) 1.35

The effect of pindolol on exercise-induced cardiac acceleration in relation to plasma levels in man. Clin Pharmacol Ther (1975) 1.33

Pharmacokinetics of indomethacin. Clin Pharmacol Ther (1975) 1.31

Acetylation pharmacogenetics. The slow acetylator phenotype is caused by decreased or absent arylamine N-acetyltransferase in human liver. J Clin Invest (1990) 1.30

Pharmacokinetics of (+)-, (-)- and (+/-)-verapamil after intravenous administration. Br J Clin Pharmacol (1984) 1.30

Cytochrome P450 induction by rifampicin in healthy subjects: determination using the Karolinska cocktail and the endogenous CYP3A4 marker 4beta-hydroxycholesterol. Clin Pharmacol Ther (2008) 1.29

Letter: Sodium valproate and platelet function. Br Med J (1976) 1.29

Interphenotype differences in disposition and effect on gastrin levels of omeprazole--suitability of omeprazole as a probe for CYP2C19. Br J Clin Pharmacol (1995) 1.28

Indole-3-acetic acid in human cerebrospinal fluid: identification and quantification by mass fragmentography. Science (1972) 1.27

The genetic polymorphism of sparteine metabolism. Xenobiotica (1986) 1.27

Methylation of mercury compounds by methylcobalamin. Biochemistry (1971) 1.27

The influence of enzyme induction on polymorphic sparteine oxidation. Br J Clin Pharmacol (1986) 1.26

A novel mutant variant of the CYP2D6 gene (CYP2D6*17) common in a black African population: association with diminished debrisoquine hydroxylase activity. Br J Clin Pharmacol (1996) 1.26

The influence of environmental and genetic factors on CYP2D6, CYP1A2 and UDP-glucuronosyltransferases in man using sparteine, caffeine, and paracetamol as probes. Pharmacogenetics (1994) 1.25

"Serotonin depression"--a biochemical subgroup within the affective disorders? Science (1976) 1.24

Drug metabolism in thyroid disease. Clin Pharmacokinet (1976) 1.24

Pharmacokinetics, bioavailability and ECG response of verapamil in patients with liver cirrhosis. Br J Clin Pharmacol (1981) 1.23

Pharmacokinetics and biological effects of nortriptyline in man. Acta Pharmacol Toxicol (Copenh) (1971) 1.21

Ultrarapid hydroxylation of debrisoquine in a Swedish population. Analysis of the molecular genetic basis. J Pharmacol Exp Ther (1995) 1.21

Antipyrine metabolism in relation to polymorphic oxidations of sparteine and debrisoquine. Br J Clin Pharmacol (1983) 1.21

Disposition of quercetin in man after single oral and intravenous doses. Eur J Clin Pharmacol (1975) 1.21

Distribution and elimination kinetics of carbamazepine in man. Eur J Clin Pharmacol (1975) 1.20

Extensive metabolizers of debrisoquine become poor metabolizers during quinidine treatment. Pharmacol Toxicol (1987) 1.20

Inter- and intra-subject variation in the first-pass elimination of highly cleared drugs during chronic dosing. Studies with deuterated verapamil. Eur J Clin Pharmacol (1984) 1.20

Use of omeprazole as a probe drug for CYP2C19 phenotype in Swedish Caucasians: comparison with S-mephenytoin hydroxylation phenotype and CYP2C19 genotype. Pharmacogenetics (1995) 1.20

Inter-ethnic difference in sparteine oxidation among Ghanaians and Germans. Eur J Clin Pharmacol (1985) 1.18

CYP3A genetics in drug metabolism. Nat Med (2001) 1.17

Determination of verapamil in human plasma by mass fragmentography using stable isotope-labelled verapamil as internal standard. Arzneimittelforschung (1977) 1.17

Genetically variable metabolism of antidepressants and neuroleptic drugs in man. Pharmacogenetics (1993) 1.16

Effects of verapamil on P-R-intervals in relation to verapamil plasma levels following single I.V. and oral administration and during chronic treatment. Klin Wochenschr (1980) 1.16

Polymorphic hydroxylation of S-mephenytoin and omeprazole metabolism in Caucasian and Chinese subjects. Pharmacogenetics (1992) 1.16

Effect of rifampicin and CYP2B6 genotype on long-term efavirenz autoinduction and plasma exposure in HIV patients with or without tuberculosis. Clin Pharmacol Ther (2011) 1.15

Pharmacokinetics of midazolam in relation to polymorphic sparteine oxidation. Br J Clin Pharmacol (1986) 1.14

Slow hydroxylation of nortriptyline and concomitant poor debrisoquine hydroxylation: clinical implications. Lancet (1981) 1.14

Results from a nationwide postmarketing cohort study of patients in Sweden treated with etanercept. Ann Rheum Dis (2004) 1.14

Elucidation of the genetic basis of the common 'intermediate metabolizer' phenotype for drug oxidation by CYP2D6. Pharmacogenetics (2000) 1.13

Nortriptyline and antipyrine clearance in relation to debrisoquine hydroxylation in man. Life Sci (1980) 1.13